{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T07:10:28Z","timestamp":1773645028747,"version":"3.50.1"},"reference-count":41,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T00:00:00Z","timestamp":1715990400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T00:00:00Z","timestamp":1715990400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pediatric Blood &amp;amp; Cancer"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    This systematic literature review evaluated frontline treatment burden in pediatric and adolescent\/young adult (AYA) patients with high\u2010risk classical Hodgkin lymphoma (cHL) among studies originating from the United States. Data were extracted from 32 publications (screened: total,\n                    <jats:italic>n<\/jats:italic>\n                    \u00a0=\u00a03115; full\u2010text,\n                    <jats:italic>n<\/jats:italic>\n                    \u00a0=\u00a098) representing 12 studies (randomized controlled trials [RCTs],\n                    <jats:italic>n<\/jats:italic>\n                    \u00a0=\u00a02; non\u2010comparative, non\u2010randomized,\n                    <jats:italic>n<\/jats:italic>\n                    \u00a0=\u00a07; observational,\n                    <jats:italic>n<\/jats:italic>\n                    \u00a0=\u00a03). High\u2010risk disease definitions varied across studies. Five\u2010year event\u2010free survival (EFS)\/progression\u2010free survival (PFS) was 86%\u2013100% and 79%\u201394%, and complete response rates were 35%\u2013100% and 5%\u201364% for brentuximab vedotin (BV)\u2010containing and chemotherapy\u2010alone regimens, respectively. In identified RCTs, BV\u2010containing compared with chemotherapy\u2010alone regimens demonstrated significantly longer 3\u2010year EFS\/5\u2010year PFS. Hematological and peripheral neuropathy were the most commonly reported adverse events of interest, although safety data were inconsistently reported. Few studies evaluated humanistic and no studies evaluated economic burden. Results from studies with the highest quality of evidence indicate an EFS\/PFS benefit for frontline BV\u2010containing versus chemotherapy\u2010alone regimens for pediatric\/AYA patients with high\u2010risk cHL.\n                  <\/jats:p>","DOI":"10.1002\/pbc.31027","type":"journal-article","created":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T03:46:43Z","timestamp":1716004003000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A systematic literature review of clinical evidence and treatment burden in newly diagnosed high\u2010risk pediatric patients with classical Hodgkin lymphoma"],"prefix":"10.1002","volume":"71","author":[{"given":"Jamie E.","family":"Flerlage","sequence":"first","affiliation":[{"name":"Department of Pediatrics Hematology and Oncology University of Rochester Medical Center  Rochester New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Waters\u2010Banker","sequence":"additional","affiliation":[{"name":"Maple Health Group, LLC  New York New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Fanale","sequence":"additional","affiliation":[{"name":"Pfizer Inc.  Bothell Washington USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Beckerman","sequence":"additional","affiliation":[{"name":"Maple Health Group, LLC  New York New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon M.","family":"Castellino","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Emory University School of Medicine  Atlanta Georgia USA"},{"name":"Aflac Cancer and Blood Disorders Center Children's Healthcare of Atlanta  Atlanta Georgia USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2468-9482","authenticated-orcid":false,"given":"Nicholas","family":"Liu","sequence":"additional","affiliation":[{"name":"Pfizer Inc.  Bothell Washington USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,5,18]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-0189-6"},{"key":"e_1_2_10_3_1","unstructured":"National Cancer Institute.Childhood Hodgkin lymphoma treatment (PDQ) \u2010 Health professional version.National Cancer Institute. Accessed June 1 2023.https:\/\/www.cancer.gov\/types\/lymphoma\/hp\/child\u2010hodgkin\u2010treatment\u2010pdq"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2021.7042"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34479"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.07.131"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26717"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28562"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.4853"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(17)32134\u20107"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470\u20102045(18)30784\u20108"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2017.75.2543"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1510093"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/s2352\u20103026(21)00101\u20100"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005150"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000719"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(21)00102-2"},{"key":"e_1_2_10_18_1","unstructured":"Centre for Reviews and Dissemination (CRD).CRD's guidance for undertaking reviews in healthcare. CRD. Accessed June 1 2023.https:\/\/www.york.ac.uk\/media\/crd\/Systematic_Reviews.pdf"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-10-184143"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206660"},{"issue":"2","key":"e_1_2_10_22_1","first-page":"351","article-title":"Brentuximab vedotin with chemotherapy in adolescents and young adults (AYAs) with stage III or IV Hodgkin lymphoma: a subgroup analysis from the phase 3 ECHELON\u20101 study","volume":"5","author":"Grigg AP","year":"2021","journal-title":"Hemasphere"},{"issue":"5","key":"e_1_2_10_23_1","first-page":"S78","article-title":"Results from an open\u2010label, phase 1\/2 study of frontline brentuximab vedotin plus adriamycin, vinblastine, and dacarbazine in pediatric patients with advanced stage Hodgkin lymphoma","volume":"68","author":"Franklin A","year":"2021","journal-title":"Pediatr Blood Cancer"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004445"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16014"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-285379"},{"issue":"3","key":"e_1_2_10_27_1","first-page":"41","article-title":"P103 (0152) Stanford v chemotherapy and low dose radiotherapy for children and adolescents with unfavorable and intermediate risk Hodgkin lymphoma: results of a multi\u2010institutional prospective clinical trial","volume":"2","author":"Metzger M","year":"2018","journal-title":"Hemasphere"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03286"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-129301"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0000000000001094"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-135935"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.10064"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.e18927"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-112664"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1097\/JOM.0000000000000277"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.5410"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00470-8"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206125"},{"key":"e_1_2_10_39_1","unstructured":"Clinicaltrials.gov.Pediatric classical Hodgkin lymphoma consortium study: cHOD17.NIH. Accessed October 30 2023.https:\/\/clinicaltrials.gov\/study\/NCT03755804"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102023\u2010187125"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1186\/s41687\u2010023\u201000653\u20100"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.65.4194"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.31027","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/pbc.31027","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.31027","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T06:38:10Z","timestamp":1773643090000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.31027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,18]]},"references-count":41,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["10.1002\/pbc.31027"],"URL":"https:\/\/doi.org\/10.1002\/pbc.31027","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,18]]},"assertion":[{"value":"2023-12-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e31027"}}